Core Insights - CERo Therapeutics has received FDA approval for an amendment to its IND regarding Chemistry, Manufacturing, and Controls (CMC), allowing the company to initiate patient dosing in the first half of 2025 [1][2] - The company has also had an abstract accepted for presentation at the 2025 ASCO conference, scheduled for May 30 to June 5 in Chicago [2] - The Phase 1/1b clinical trial for CER-1236 will evaluate its safety and preliminary efficacy in patients with relapsed/refractory measurable residual disease positive acute myeloid leukemia [2][3] Company Overview - CERo Therapeutics is focused on developing next-generation engineered T cell therapeutics for cancer treatment, utilizing a proprietary approach that combines innate and adaptive immunity [3] - The company aims to create Chimeric Engulfment Receptor T cells (CER-T) that can potentially target both hematological malignancies and solid tumors, offering a differentiated therapeutic application compared to existing CAR-T therapies [3]
CERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing